Abstract
The tumor-specific immunoglobulin (Ig) expressed by B-cell malignancies can serve as a target for passive or active immunotherapy. This target, referred to as the “idiotype” (Id), is composed of the unique antigenic determinants in the variable regions of the clonal Ig heavy and light chains expressed by the tumor cells (Timmerman and Levy 2000). This protein target has the unusual nature of being unique in every B-cell cancer (Fig. 1). The human immune system contains billions of different B cells, each with a unique Ig polypeptide sequence resulting from the physiologic rearrangement and somatic mutation of gene segments during B-cell differentiation. The Ig is expressed on the B-cell surface to serve as an antigen receptor (B-cell receptor, BCR).
References
Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Mellstedt H, Osterborg A. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol. 2007a;79(5):371–81.
Abdalla AO, Hansson L, Eriksson I, et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma – evaluation of T-cell responses by different read-out systems. Haematologica. 2007b;92(1):110–4.
Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 2008;19(6):1172–9.
Barrios Y, Cabrera R, Yanez R, et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica. 2002;87(4):400–7.
Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments]. Nat Med. 1999;5(10):1171–7.
Bertinetti C, Simon F, Zirlik K, et al. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol. 2006a;77(5):395–402.
Bertinetti C, Zirlik K, Heining-Mikesch K, et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 2006b;66(8):4496–502.
Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior anti-tumor immunity against B cell lymphomas. J Immunol. 2008;181:4131–40.
Bogen B, Ruffini PA, Corthay A, et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica. 2006;91(7):941–8.
Carey GB, Donjerkovic D, Mueller CM, et al. B-cell receptor and Fas-mediated signals for life and death. Immunol Rev. 2000;176:105–15.
Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood. 1998;92(4):1184–90.
Eeva J, Pelkonen J. Mechanisms of B cell receptor induced apoptosis. Apoptosis. 2004;9(5):525–31.
Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27(18):3036–43.
Hall SS. Dr. Levy’s favorite guinea pig, A commotion in the blood. New York: Henry Holt & Company; 1997. p. 391–408.
Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood. 2003;101(12):4930–6.
Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13(5):1503–10.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52–8.
Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma – long-term results of a clinical trial. Blood. 1997;89(9):3129–35.
Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98(18):1292–301.
Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol. 2009;46(3):448–56.
Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood. 2007;109(8):3393–9.
Kim SB, Baskar S, Kwak LW. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymphoma. 2003;44(7):1201–8.
Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209–15.
Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A. 1996;93(20):10972–7.
Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A. 1978;75(5):2411–5.
Levy R, Robertson MJ, Ganjoo K, Leonard JP, Vose J, Denney D. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin’s lymphoma (fNHL). Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 12–16 Apr 2008; San Diego, CA Philadelphia (PA): AACR; 2008 Abstract LB-204 2008.
Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000;96(8):2828–33.
Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A. 1972;69(6):1540–4.
Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80(6):1502–10.
McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A. 1999;96(2):703–8.
Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312(26):1658–65.
Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517–22.
Miller RA, Hart S, Samoszuk M, et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med. 1989;321(13):851–7.
Niiro H, Maeda A, Kurosaki T, Clark EA. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J Exp Med. 2002;195(1):143–9.
Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood. 2003;101(11):4607–10.
Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol. 2006;24(19):3107–12.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.
Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant. 1997;3(3):157–63 [9310193].
Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood. 1999;93(7):2411–9.
Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A. 2002;99(11):7588–93.
Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol. 2009;27(suppl; abstr 2):15s. ASCO Plenary Session, May 31, 2009.
Schuster SJ, Santos CF, Neelapu SS, et al. Vaccination with IgM but not IgG idiotype prolongs remission duration in follicular lymphoma patients. Blood. 2010;American Society of Hematology Annual Meeting Abstracts, 116: Abstract 429.
Stevenson FK, Elliott EV, Stevenson GT. Some effects on leukaemic B lymphocytes of antibodies to defined regions of their surface immunoglobulin. Immunology. 1977;32(4):549–57.
Timmerman JM. Therapeutic idiotype vaccines for non-Hodgkin’s lymphoma. Adv Pharmacol. 2004;51:271–93.
Timmerman JM, Levy RL. The history of the development of vaccines for lymphoma. Clin Lymphoma. 2000;1:129–39.
Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99(5):1517–26.
Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37–46.
Varghese B, Widman A, Do J, et al. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood. 2009;114:4477–85.
Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83(4):899–906.
Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22(23):4717–24.
Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol. 2011;344:193–210.
Yanez R, Barrios Y, Ruiz E, Cabrera R, Diaz-Espada F. Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study. J Immunother. 2008;31(3):310–2.
Yi Q, Szmania S, Freeman J, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010;150(5):554–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Timmerman, J.M. (2013). Anti-Idiotype Antibodies. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_51-2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6613-0_51-2
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-6613-0
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences